Designing and Comparison of Two Types of Chitosan Nanogels for Doxorubicine Delivery

Authors
F. Atabi 1
S. L. Mousavi Gargari 2
M. Hashemi 3
P. Yaghmaei 1
1 Department of Biology, Faculty of Basic Sciences, Science and Research Branch, Islamic Azad University, Tehran, Iran
2 Department of Biology, Faculty of Science, Shahed University, Tehran, Iran
3 Department of Genetics, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran
Abstract
Objective: Drug delivery systems related to different cancer therapies is now expanding. Chitosan (CS) is currently receiving enormous interest for medical and pharmaceutical applications due to its biocompatibility in animal tissues. In this study, two nanogels were prepared from CS. Some of the critical factors such as controlling the release, adsorption and specially targeting drug delivery are considered while preparing the nanogels.
Methods: Phosphorylated CS (PCS) and Myristilated CS (MCS) nanogels were prepared by reacting CS with tripolyphosphate (TPP) and Myristate as cross-linking agents respectively and then were loaded with Doxorubicin (DOX). The nanogels were characterized by different techniques such as scanning electron microscopy, dynamic light scattering and Fourier-transform infrared. The cytotoxicity of free DOX, MCS nanogels and DOX loaded MCS was evaluated by the MTT assay.
Results: The result of DOX loading and releasing of the nanogels showed high loading capacity and drug loading efficiency of about 97%. Results indicated slow release of about 16-28% of DOX from PCS within 5 days and 18-40% from MCS within 15 days. DOX and MCS-DOX showed the same toxic effect on the prostate cancer cells (LNCaP).
Conclusion: Both PCS and MCS nanogels were qualified on the basis of size, loading and releasing capacity.

Keywords

[1]  Cox JC, Hayhurst A, Hesselberth J, Bayer TS, Georgiou G, Ellington AD. Automated selection of aptamers against protein targets translated in vitro: from gene to aptamer. Nucleic Acids Res 2002; 30(20): e108.
[2]  Bravo-Osuna I, Vauthier C, Chacun H, Ponchel G. Specific permeability modulation of intestinal paracellular pathway by chitosan-poly(isobutylcyanoacrylate) core-shell nanoparticles. Eur J Pharm Biopharm 2008; 69(2): 436-44.
[3]  Rees M, Moghimi SM. Nanotechnology: from fundamental concepts to clinical applications for healthy aging. Maturitas 2012; 73(1): 1-4.
[4]  Shi P, Gustafson JA, MacKay JA. Genetically engineered nanocarriers for drug delivery. Int J Nanomedicine 2014; 9: 1617-26.
[5]  Sonia TA, Sharma CP. Chitosan and Its Derivatives for Drug Delivery Perspective. Adv Polym Sci 2011; 243: 23-54.
[6]  Raj L, Chauhan GS, Azmi W, Ahn JH, Manuel J. Kinetics study of invertase covalently linked to a new functional nanogel. Bioresour Technol 2011; 102(3): 2177-84.
[7]  Cifani N, Chronopoulou L, Pompili B, Di Martino A, Bordi F, Sennato S, Di Domenico EG, Palocci C, Ascenzioni F. Improved stability and efficacy of chitosan/pDNA complexes for gene delivery. Biotechnol Lett 2015; 37(3): 557-65.
[8]  Morris G, Kök S, Harding S, Adams G. Polysaccharide drug delivery systems based on pectin and chitosan. Biotechnol Genet Eng Rev 2010; 27: 257-84.
[9]  Aranaz I, Harris R, Heras A. Chitosan amphiphilic derivatives. Chemistry and applications. Curr Organic Chem 2010; 14(3): 308-30.
[10] Yang X, Zhang X, Liu Z, Ma Y, Huang Y, Chen Y. High-efficiency loading and controlled release of doxorubicin hydrochloride on graphene oxide. J Physic Chem 2008; 112(45): 17554-8.
[11] Kim YT, Yum S, Heo JS, Kim W, Jung Y, Kim YM. Dithiocarbamate chitosan as a potential polymeric matrix for controlled drug release. Drug Dev Ind Pharm 2014; 40(2): 192-200.
[12] Hauser-Kawaguchi AMN, Luyt LG. Nanomedicine_ Nanoparticles in Cancer Imaging and Therapy. Genomic Instab Canc Metastas 2015; 20: 205-44.
[13] Taranejoo S, Janmaleki M, Rafienia M, Kamali M, Mansouri M. Chitosan microparticles loaded with exotoxin A subunit antigen for intranasal vaccination against Pseudomonas aeruginosa: An in vitro study. Carbohydrete Polymers 2011; 83(4): 1854-61.
[14] Zhang H, Oh M, Allen C, Kumacheva E. Monodisperse chitosan nanoparticles for mucosal drug delivery. Biomacromolecules 2004; 5(6): 2461-8.
[15] Rossi S, Ferrari F, Bonferoni MC, Sandri G, Faccendini A, Puccio A, Caramella C. Comparison of poloxamer- and chitosan-based thermally sensitive gels for the treatment of vaginal mucositis. Drug Dev Ind Pharm 2014; 40(3): 352-60.
 
[16] Wang C, Mallela J, Garapati US, Ravi S, Chinnasamy V, Girard Y, Howell M, Mohapatra S. A chitosan-modified graphene nanogel for noninvasive controlled drug release. Nanomedicine 2013; 9(7): 903-11.
[17] Tsai ML, Bai SW, Chen RH. Cavitation effects versus stretch effects resulted in different size and polydispersity of ionotropic gelation chitosan G_O sodium tripolyphosphate nanoparticle. Carbohydrate Polymers 2008; 71: 448-57.
[18] Figuerola A, Di Corato R, Manna L, Pellegrino T. From iron oxide nanoparticles towards advanced iron-based inorganic materials designed for biomedical applications. Pharmacol Res 2010; 62(2): 126-43.
[19] Jayakumar R, Nair A, Sanoj Rejinold N, Maya S, Nair SV. Doxorubicin-loaded pH-responsive chitin nanogels for drug delivery to cancer cells. Carbohydrate Polymers 2012; 87(3): 2352-6.
[20] Mitra T, Sailakshmi G, Gnanamani A, Mandal AB. Studies on cross-linking of succinic acid with chitosan/collagen. Mat Res 2013; 16(4): 755-65.
[21] Reddy LH. Drug delivery to tumours: recent strategies. J Pharm Pharmacol 2005; 57(10): 1231-42.
[22] Liu Z, Chen K, Davis C, Sherlock S, Cao Q, Chen X, Dai H. Drug delivery with carbon nanotubes for in vivo cancer treatment. Cancer Res 2008; 68(16): 6652-60.
Pathobiology Reserach
Volume 18, Issue 2
June 2015
Pages 53-67